Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1955 - A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight (BW) and Platelet (plt) Count: Blinded Pooled Interim Safety Data from the NORA Study

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Breast Cancer

Presenters

Xiaohua Wu

Citation

Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250

Authors

X. Wu1, J. Zhu2, R. Yin3, J. Yang4, L. Wu5, J. Liu6, Z. Liu7, J. Wang8, Y. Gao9, D. Wang10, G. Lou11, H. Yang12, B. Kong13, Y. Huang14, Q. Zhou15, H. Wen1, J. Hou16, C. Zhang16, Y. Hei16

Author affiliations

  • 1 Department Of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Department Of Gynecologic Oncology, Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
  • 3 Key Laboratory Of Obstetrics & Gynecologic And Pediatric Diseases And Birth Defects Of Ministry Of Education, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, 610066 - Chengdu/CN
  • 4 Key Laboratory Of Carcinogenesis And Translational Research (ministry Of Education/beijing), Department of Gynecology, Peking University Cancer Hospital & Institute, 100142 - Beijing/CN
  • 5 Department Of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 6 Department Of Gynecologic Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 7 Department Of Oncology, The First Hospital of Jilin University, 130021 - Changchun/CN
  • 8 Department Of Gynecologic Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013 - Changsha/CN
  • 9 Key Laboratory Of Carcinogenesis And Translational Research (ministry Of Education/beijing), Department of Gynecology, Peking University Cancer Hospital & Institute, 100730 - Beijing/CN
  • 10 Department Of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, 110042 - Shenyang/CN
  • 11 Department Of Gynecology And Oncology, The Affiliated Tumor Hospital of Harbin Medical University, 150081 - Harbin/CN
  • 12 Department Of Gynecology, Yunnan Cancer Hospital & Yunnan Cancer Center & The Third Affiliated Hospital of Kunming Medical University, 650118 - Kunming/CN
  • 13 Department Of Obstetrics And Gynecology, Qilu Hospital, Shandong University, 250012 - Jinan/CN
  • 14 Department Of Gynecologic Oncology, Hubei Cancer Hospital, 430079 - Wuhan/CN
  • 15 Department Of Gynecologic Oncology, Chongqing Cancer Hospital, 400030 - Chongqing/CN
  • 16 R&d Department, Zai Lab (Shanghai) Co., Ltd, 201210 - Shanghai/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1955

Background

Niraparib is a highly selective PARP-1/-2 inhibitor approved by FDA for the maintenance therapy of platinum-sensitive recurrent (PSR) ovarian cancer based on the significantly improved progression-free survival for niraparib-treated patients (pts) in the phase III NOVA study. A retrospective analysis of NOVA study suggests that pts with BW <77 kg or baseline plt count <150*109/L may have an improved safety profile from a starting dose of 200 mg once daily (QD) without compromising efficacy. A double-blinded, 2:1 randomized, placebo-controlled phase III study (NORA) is being conducted in China to investigate niraparib as maintenance therapy in Chinese pts with PSR ovarian cancer. The dosing regimen in the study was 300 mg QD but the study protocol was subsequently amended to have a starting dose of either 300 or 200 mg of niraparib/placebo QD based on baseline BW and plt counts. The trial has completed accrual and remains blinded for efficacy and safety. The current analysis was intended to evaluate niraparib tolerability for pts starting treatment with an individualized starting dose and compare with that in pts with the fixed starting dose of 300 mg QD.

Methods

The initial protocol adopted a fixed starting dose of 300 mg QD. After 16 patients were enrolled, the protocol was amended to start niraparib treatment at a dose of 200 mg QD in pts with BW <77 kg or plt count <150*109/L, and 300 mg for others. Blinded data were pooled from niraparib and placebo arms.

Results

A total of 265 pts had been enrolled, and 232 pts who have been followed up ≥ 90 days ending Mar 31, 2019 were included in this analysis. There were no major differences in key pts demographics or disease characteristics between both arms. Key safety data are presented in the table. More detailed safety data in all population will be disclosed.Table: 1004P

Pre-Amendment, Fixed starting dose (pooled niraparib and placebo arms)Post-Amendment, Individualized starting dose (pooled niraparib and placebo arms )
300 mg (N = 16)300 mg (N = 14)200 mg (N = 202)Total (N = 216)
Median BW, kg (min, max)62 (40,76)83 (78,94)59 (37,82)61 (37,94)
Median plt count,109/L (min, max)211 (124,336)187(153,325)184 (62,447)184 (62,447)
Any ≥ grade 3 TEAE, n(%)9 (56.3)4 (28.6)56 (27.7)60 (27.8)
≥Grade 3 thrombocytopenia, n(%)3 (13.8)1 (7.1)6 (3.0)7 (3.2)
≥Grade 3 anemia, n(%)4 (25.0)2 (14.3)9 (4.5)11 (5.1)
≥Grade 3 neutropenia, n(%)2 (12.5)025 (12.4)25 (11.6)
Any serious TEAE, n(%)4 (25.0)1 (7.1)19 (9.4)20 (9.3)
TEAE leading to end of treatment, n (%)1 (6.3)03 (1.5)3 (1.4)

Conclusions

The results indicate that niraparib tolerability will be improved with a starting dose based on body weight or platelet count.

Clinical trial identification

NCT03705156.

Editorial acknowledgement

Jun Wan and John Zhang of Zai Lab Writing and coordinated by Sean Li and Wendy Zhang of Zai Lab, Inc, funded by Zai Lab, Inc. (Shanghai,China).

Legal entity responsible for the study

Zai Lab (Shanghai) Co., Ltd.

Funding

Zai Lab (Shanghai) Co., Ltd.

Disclosure

J. Hou: Full / Part-time employment: Zai Lab (Shanghai) Co., Ltd C. Zhang: Full / Part-time employment: Zai Lab (Shanghai) Co., Ltd Y. Hei: Full / Part-time employment: Zai Lab (Shanghai) Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.